Trial · NCT05954780
Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
NCT05954780, Active not recruiting, iOMEDICO AG
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma. Trials, record NCT05954780. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05954780
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma
- NCT number
- NCT05954780
- Status
- Active not recruiting
- Enrollment
- 75 participants, actual
- Lead sponsor
- iOMEDICO AG
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor
- First posted
- 2023-07-20
- Last updated
- 2026-01-14
Source ClinicalTrials.gov
Registered outcomes42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline of EORTC global health scale | Baseline, up to 40 months | Change from baseline quality of life (QoL) over time for the global health scale of the EORTC QLQ- C30 questionnaire. |
| Secondary | Change from baseline of EORTC QLQ-C30 further scales | Baseline, up to 40 months | Change from baseline in further scales of the EORTC QLQ-C30 questionnaire |
| Secondary | Change from baseline of EORTC QLQ-MY20 further scales | Baseline, up to 30 days after selinexor treatment | Change from baseline in further scales of the EORTC QLQ-MY20 questionnaire |
| Secondary | Assessment of drug tolerability and safety | Baseline, up to 40 months | Frequency of specific (serious) adverse drug reactions ((S)ADRs) (nausea, weight loss, diarrhea, vomiting, fatigue) |
| Secondary | Adverse events (AEs) and serious adverse events (SAEs) according to NCI CTCAE | Baseline, up to 30 days after end of selinexor treatment | Incidence of (serious) AEs ((S)AEs) as characterized by type, frequency, severity and seriousness. |
| Secondary | Adverse drug reaction (ADR) and serious adverse drug reactions (SADR) | Baseline, up to 30 days after end of selinexor treatment | Incidence of (serious) adverse drug reactions ((S)ADRs) as characterized by type, frequency, severity and seriousness. |
| Secondary | Adverse events of special interest (AESI) | Baseline, up to 30 days after end of selinexor treatment | Incidence of AEs of special interest defined as cataracts (new-onset cataracts and worsening of cataracts) and Acute cerebellar syndrome. |
| Secondary | Changes in selinexor therapy | From date of selinexor treatment start, up to 40 months | Frequency of treatment delays, no administrations (skips), discontinuation (withdrawn) of selinexor due to safety reasons |
| Secondary | Effectiveness in routine treatment: Best response | Baseline, up to 40 months | Frequencies of best response during selinexor therapy will be calculated using descriptive statistics. |
| Secondary | Effectiveness in routine treatment: Overall response rate (ORR) | Baseline, up to 40 months | ORR of patients will be calculated. ORR is defined as the proportion of patients achieving a complete response, very good partial response or partial response as best overall response. Patients without response measurement are considered non-responders. |
1 to 10 of 42Source ClinicalTrials.gov
See all 42 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05954780
GET https://conductscience.org/api/trials/v1/NCT05954780/registered?page=2